אסטוניה - אסטונית - Ravimiamet

teva b.v. - pemetrekseed - infusioonilahuse kontsentraadi pulber - 500mg 1tk

אסטוניה - אסטונית - Ravimiamet

mylan s.a.s. - pemetrekseed - infusioonilahuse kontsentraadi pulber - 500mg 1tk

אסטוניה - אסטונית - Ravimiamet

pharmaswiss ceska republika s.r.o. - pemetrekseed - infusioonilahuse kontsentraadi pulber - 500mg 1tk

אסטוניה - אסטונית - Ravimiamet

koanaa healthcare gmbh - pemetrekseed - infusioonilahuse kontsentraadi pulber - 100mg 1tk

אסטוניה - אסטונית - Ravimiamet

pharmaswiss ceska republika s.r.o. - pemetrekseed - infusioonilahuse kontsentraadi pulber - 100mg 1tk

האיחוד האירופי - אסטונית - EMA (European Medicines Agency)

baxter holding b.v. - pemetrexed disodium heptahydrate - carcinoma, non-small-cell lung; mesothelioma - antineoplastilised ained - malignant pleural mesotheliomapemetrexed baxter in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. non-small cell lung cancerpemetrexed baxter in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5. pemetrexed baxter is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy (see section 5. pemetrexed baxter is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5.